ESMO Congress Highlights Oncology Breakthroughs Amid Market Volatility and Fed Uncertainty
The European Society for Medical Oncology (ESMO) Congress in Madrid has showcased significant clinical advancements, with several companies reporting improved survival rates in cancer trials. AstraZeneca (AZN) reported doubled median survival for a stomach cancer drug, while Roche (RHHBY) saw its KRAS inhibitor outperform rivals from Amgen and Bristol-Myers Squibb. However, Moderna (MRNA) faced a pre-market sell-off after personalized vaccine data failed to meet high expectations. In broader markets, U.S. equities have faced downward pressure driven by AI spending concerns and rising oil prices, with Brent crude hitting a six-month high near $116.72 due to Middle East tensions. Investors are now pivoting toward key macroeconomic indicators, specifically the Federal Reserve's upcoming interest rate decision and Thursday's PCE inflation report, which will likely dictate market volatility and the trajectory of growth stocks.
Tickers: $AMGN $AZN $BMY $LLY $META $MRK $MRNA $RHHBY $SMMT
Topics: Clinical Trial Results Drug Development ESMO Congress Oncology